Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream

    July 2021 in “ Pharmaceutics
    Paul Smith, Wenqing Yao, Stacey Shepard, Maryanne Covington, James A. Lee, Jennifer H. Lofland, Ahmad Naim, Trupti Sheth, Bhavnish Parikh, Swamy Yeleswaram
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Studysummary This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    6 / 6 results